The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0 O
- O
900 O
) O
. O

Hazard O
ratios O
( O
HRs O
) O
for O
comparing O
thalidomide O
against O
placebo O
were O
estimated O
using O
Cox O
regression O
modeling O
. O

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3 I-Claim
- I-Claim
drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti I-Claim
- I-Claim
TNF I-Claim
therapy I-Claim
. I-Claim

Suggestions O
for O
future O
studies O
include O
the O
use O
of O
three O
- O
group O
designs O
( O
e O
. O
g O
. O
, O
comparing O
two O
active O
interventions O
with O
a O
standard O
- O
care O
control O
) O
and O
examining O
mechanisms O
of O
change O
. O

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first I-Claim
- I-Claim
line I-Claim
treatment I-Claim
for I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

One O
thousand O
eighty O
- O
eight O
women O
were O
randomly O
allocated O
to O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
by O
axillary O
clearance O
if O
the O
sentinel O
node O
was O
positive O
or O
not O
detected O
( O
SNBM O
) O
or O
routine O
axillary O
clearance O
( O
RAC O
, O
sentinel O
- O
lymph O
- O
node O
biopsy O
followed O
immediately O
by O
axillary O
clearance O
) O
. O

The B-Premise
use I-Premise
of I-Premise
IMRT I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
, O
but O
the B-Premise
presence I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
did I-Premise
significantly I-Premise
correlate I-Premise
with I-Premise
pain I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
and I-Premise
a I-Premise
reduced I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
003 I-Premise
) I-Premise
. I-Premise

Progression B-Premise
- B-Premise
free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1 I-Premise
. I-Premise
07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0 I-Premise
. I-Premise
92 I-Premise
to I-Premise
1 I-Premise
. I-Premise
24 I-Premise
) I-Premise
. I-Premise

In O
this O
large O
randomized O
trial O
, O
thalidomide B-Claim
in I-Claim
combination I-Claim
with I-Claim
chemotherapy I-Claim
did I-Claim
not I-Claim
improve I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
SCLC I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
an I-Claim
increased I-Claim
risk I-Claim
of I-Claim
thrombotic I-Claim
events I-Claim
. I-Claim

Randomisation O
was O
done O
in O
blocks O
of O
12 O
- O
20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer O
- O
generated O
sequence O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8 O
- O
week O
upper O
- O
body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

The O
fat O
content O
of O
the O
artificial O
diet O
was O
66 O
% O
of O
the O
nonprotein O
calories O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1 I-Premise
\/ I-Premise
G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

After O
discharge O
, O
symptom O
severity O
, O
temperature O
, O
and O
medications O
used O
were O
recorded O
daily O
for O
1 O
week O
and O
symptom O
levels O
were O
measured O
for O
weeks O
2 O
- O
4 O
. O

No B-Premise
relevant I-Premise
differences I-Premise
in I-Premise
adverse I-Premise
effects I-Premise
were I-Premise
observed I-Premise
among I-Premise
the I-Premise
groups I-Premise
during I-Premise
either I-Premise
the I-Premise
titration I-Premise
phase I-Premise
and I-Premise
chronic I-Premise
treatment I-Premise
. I-Premise

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ O
- O
C30 O
and O
the O
lung O
cancer O
module O
QLQ O
- O
LC13 O
. O

The O
CCSP O
intervention O
was O
taught O
2 O
week O
before O
hospital O
admission O
with O
reinforcement O
at O
specified O
times O
during O
treatment O
and O
3 O
months O
after O
discharge O
. O

Doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT I-Premise
- I-Premise
11 I-Premise
+ I-Premise
LFA I-Premise
5 I-Premise
- I-Premise
FU I-Premise
. I-Premise

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
"""" O
; O
"""" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

Despite B-Premise
slow I-Premise
initial I-Premise
symptom I-Premise
improvement I-Premise
, I-Premise
GJJ B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
long I-Claim
- I-Claim
term I-Claim
results I-Claim
and I-Claim
is I-Claim
therefore I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
in I-Claim
patients I-Claim
with I-Claim
a I-Claim
life I-Claim
expectancy I-Claim
of I-Claim
2 I-Claim
months I-Claim
or I-Claim
longer I-Claim
. I-Claim

Adjusted B-Premise
linear I-Premise
mixed I-Premise
- I-Premise
model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6 I-Premise
- I-Premise
month I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
the I-Premise
RET I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self I-Premise
- I-Premise
esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1 I-Premise
. I-Premise
6 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
, I-Premise
0 I-Premise
. I-Premise
1 I-Premise
- I-Premise
3 I-Premise
. I-Premise
2 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
032 I-Premise
] I-Premise
and I-Premise
the I-Premise
AET I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
- I-Premise
4 I-Premise
. I-Premise
7 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
9 I-Premise
. I-Premise
3 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

Alternating B-Claim
chemotherapy I-Claim
with I-Claim
PAV I-Claim
- I-Claim
CyMOC I-Claim
plus I-Claim
consolidating I-Claim
radiotherapy I-Claim
is I-Claim
a I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
treatment I-Claim
for I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
, I-Claim
with I-Claim
acceptable I-Claim
toxicity I-Claim
. I-Claim

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT O
- O
B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES O
- O
D O
) O
, O
respectively O
. O

However O
, O
the O
survival O
and O
quality O
- O
of O
- O
life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

QoL O
was O
evaluated O
with O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
questionnaires O
QLQ O
- O
C30 O
and O
QLQ O
- O
LC13 O
, O
and O
the O
QoL O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
QoL O
scale O
. O

Cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise

HRQL O
was O
evaluated O
with O
the O
Short O
Form O
36 O
- O
Item O
( O
SF O
- O
36 O
) O
questionnaire O
"""" O
; O
"""" O
subscales O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
PR25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
OV28 O
and O
CX24 O
modules O
for O
sexual O
symptoms O
"""" O
; O
"""" O
and O
demographic O
questions O
. O

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6 I-Premise
. I-Premise
5 I-Premise
and I-Premise
10 I-Premise
. I-Premise
1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

The O
combination O
of O
carboplatin O
and O
paclitaxel O
is O
the O
standard O
of O
care O
for O
the O
treatment O
of O
ovarian O
cancer O
, O
yet O
rates O
of O
recurrence O
and O
death O
remain O
high O
. O

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

Between O
April O
1997 O
and O
December O
2000 O
, O
386 O
women O
with O
MBC O
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
registered O
. O

The O
mean O
age O
of O
randomised O
women O
was O
62 O
. O
8 O
( O
SD O
4 O
. O
8 O
) O
years O
. O

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non O
- O
small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

High B-Premise
self I-Premise
- I-Premise
assessed I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
reported I-Premise
by I-Premise
62 I-Premise
( I-Premise
35 I-Premise
% I-Premise
) I-Premise
of I-Premise
179 I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
, I-Premise
55 I-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
of I-Premise
160 I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
, I-Premise
and I-Premise
93 I-Premise
( I-Premise
45 I-Premise
% I-Premise
) I-Premise
of I-Premise
208 I-Premise
men I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

In B-Premise
pamidronate I-Premise
LD I-Premise
patients I-Premise
, I-Premise
event I-Premise
- I-Premise
rates I-Premise
decreased I-Premise
by I-Premise
15 I-Premise
% I-Premise
to I-Premise
45 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise

1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct O
- O
switch O
"""" O
; O
"""" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM I-Premise
- I-Premise
24 I-Premise
was I-Premise
7 I-Premise
. I-Premise
1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6 I-Premise
. I-Premise
0 I-Premise
, I-Premise
9 I-Premise
. I-Premise
0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM I-Premise
- I-Premise
24 I-Premise
of I-Premise
8 I-Premise
. I-Premise
1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7 I-Premise
. I-Premise
0 I-Premise
, I-Premise
10 I-Premise
. I-Premise
0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O

Improvement B-Claim
over I-Claim
time I-Claim
was I-Claim
evident I-Claim
in I-Claim
both I-Claim
treatment I-Claim
groups I-Claim
but I-Claim
more I-Claim
so I-Claim
for I-Claim
patients I-Claim
receiving I-Claim
placebo I-Claim
. I-Claim

QUARTZ O
is O
a O
randomised O
, O
non O
- O
inferiority O
, O
phase O
III O
trial O
comparing O
OSC O
+ O
WBRT O
versus O
OSC O
in O
patients O
with O
inoperable O
brain O
metastases O
from O
NSCLC O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first I-Claim
- I-Claim
generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

Data O
were O
collected O
prior O
to O
intervention O
and O
post O
- O
intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O

Proportions O
of O
patients O
with O
skeletal O
- O
related O
events O
, O
time O
to O
the O
first O
skeletal O
- O
related O
event O
, O
skeletal O
morbidity O
rate O
, O
pain O
and O
analgesic O
scores O
, O
disease O
progression O
, O
and O
safety O
were O
assessed O
. O

Vaginal B-Premise
dryness I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
064 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
016 I-Premise
- I-Premise
0 I-Premise
. I-Premise
112 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
problems I-Premise
( I-Premise
b I-Premise
= I-Premise
0 I-Premise
. I-Premise
054 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
007 I-Premise
- I-Premise
0 I-Premise
. I-Premise
102 I-Premise
) I-Premise
increased I-Premise
in I-Premise
women I-Premise
taking I-Premise
anastrozole I-Premise
compared I-Premise
with I-Premise
women I-Premise
taking I-Premise
tamoxifen I-Premise
. I-Premise

Repeated O
measurement O
analysis O
was O
performed O
for O
between O
- O
group O
analysis O
. O

Patients B-Premise
with I-Premise
extensive I-Premise
disease I-Premise
survived I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
than I-Premise
on I-Premise
the I-Premise
early I-Premise
alternation I-Premise
regimen I-Premise
( I-Premise
median I-Premise
survival I-Premise
336 I-Premise
days I-Premise
versus I-Premise
301 I-Premise
days I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post I-Claim
- I-Claim
treatment I-Claim
. I-Claim

A B-Premise
significant I-Premise
difference I-Premise
was I-Premise
evidenced I-Premise
for I-Premise
the I-Premise
worst I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
035 I-Premise
) I-Premise
. I-Premise

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

This O
open O
- O
label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
randomly O
assigned O
to O
GEM O
alone O
or O
GEM O
plus O
capecitabine O
( O
GEM O
- O
CAP O
) O
. O

QOL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
except B-Premise
for I-Premise
the I-Premise
functional I-Premise
activity I-Premise
score I-Premise
of I-Premise
the I-Premise
Rotterdam I-Premise
Symptom I-Premise
Checklist I-Premise
, I-Premise
where I-Premise
QOL I-Premise
data I-Premise
statistically I-Premise
significantly I-Premise
favored I-Premise
the I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
arm I-Premise
( I-Premise
two I-Premise
- I-Premise
sided I-Premise
P I-Premise
= I-Premise
. I-Premise
043 I-Premise
) I-Premise
. I-Premise

Amitriptyline B-Claim
is I-Claim
the I-Claim
most I-Claim
common I-Claim
analgesic I-Claim
adjuvant I-Claim
used I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
neuropathic I-Claim
pain I-Claim
, I-Claim
even O
though O
no B-Claim
specific I-Claim
studies I-Claim
have I-Claim
demonstrated I-Claim
a I-Claim
benefit I-Claim
. I-Claim

The O
inflammation O
- O
related O
cytokines O
including O
interleukin O
- O
6 O
, O
interleukin O
- O
10 O
, O
and O
tumor O
necrosis O
factor O
- O
α O
were O
also O
determined O
. O

The O
treatment O
could O
be O
incorporated O
into O
breast O
cancer O
survivorship O
programmes O
and O
delivered O
by O
trained O
breast O
cancer O
nurses O
. O

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log O
- O
rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

In B-Premise
all I-Premise
study I-Premise
groups I-Premise
, I-Premise
serum I-Premise
TSH I-Premise
levels I-Premise
showed I-Premise
very I-Premise
good I-Premise
stimulation I-Premise
( I-Premise
mean I-Premise
, I-Premise
82 I-Premise
. I-Premise
24 I-Premise
+ I-Premise
\/ I-Premise
- I-Premise
18 I-Premise
. I-Premise
21 I-Premise
mU I-Premise
\/ I-Premise
L I-Premise
) I-Premise
, I-Premise
without I-Premise
significant I-Premise
between I-Premise
- I-Premise
group I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
5213 I-Premise
) I-Premise
. I-Premise

To O
help O
document O
the O
achievement O
of O
palliation O
and O
to O
characterize O
positive O
and O
negative O
effects O
of O
treatment O
, O
we O
evaluated O
quality O
- O
of O
- O
life O
( O
QOL O
) O
parameters O
in O
patients O
with O
metastatic O
prostate O
cancer O
who O
were O
randomly O
assigned O
to O
two O
methods O
of O
androgen O
deprivation O
. O

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self O
- O
Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
General O
( O
FACT O
- O
G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

Responders O
were O
separately O
compared O
with O
nonresponders O
( O
patients O
with O
SD O
( O
6m O
) O
or O
PD O
) O
and O
with O
patients O
with O
SD O
( O
6m O
) O
, O
and O
patients O
with O
clinical O
benefit O
were O
compared O
with O
patients O
with O
PD O
by O
analysis O
of O
covariance O
with O
adjustment O
for O
baseline O
scores O
. O

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5 I-Premise
- I-Premise
year I-Premise
period I-Premise
. I-Premise

Mean B-Premise
intake I-Premise
per I-Premise
kilogram I-Premise
of I-Premise
body I-Premise
weight I-Premise
for I-Premise
the I-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
ranged I-Premise
from I-Premise
28 I-Premise
to I-Premise
31 I-Premise
kcal I-Premise
\/ I-Premise
kg I-Premise
\/ I-Premise
day I-Premise
compared I-Premise
with I-Premise
25 I-Premise
to I-Premise
29 I-Premise
kcal I-Premise
\/ I-Premise
kg I-Premise
\/ I-Premise
day I-Premise
for I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
022 I-Premise
) I-Premise
. I-Premise

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
04 I-Premise
) I-Premise
. I-Premise

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

Enzastaurin O
( O
E O
) O
inhibits O
PKCβ O
and O
PI3K O
\/ O
AKT O
signaling O
pathways O
with O
a O
dose O
- O
dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q I-Premise
- I-Premise
LES I-Premise
- I-Premise
Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

Slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
- I-Premise
Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3 I-Premise
- I-Premise
4 I-Premise
infections I-Premise
( I-Premise
5 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
. I-Premise
3 I-Premise
% I-Premise
versus I-Premise
3 I-Premise
. I-Premise
1 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
80 I-Premise
) I-Premise
. I-Premise

These B-Claim
results I-Claim
may I-Claim
have I-Claim
implications I-Claim
for I-Claim
the I-Claim
design I-Claim
of I-Claim
combination I-Claim
regimens I-Claim
incorporating I-Claim
IFN I-Claim
with I-Claim
targeted I-Claim
agents I-Claim
. I-Claim

Quality B-Premise
of I-Premise
life I-Premise
at I-Premise
4 I-Premise
years I-Premise
was I-Premise
similar I-Premise
, I-Premise
with I-Premise
the I-Premise
exception I-Premise
of I-Premise
decreased I-Premise
social I-Premise
function I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
endocrine I-Premise
treatment I-Premise
plus I-Premise
radiotherapy I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
pain I-Premise
severity I-Premise
, I-Premise
other I-Premise
postprocedural I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
medication I-Premise
use I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
but B-Premise
long I-Premise
- I-Premise
term I-Premise
relief I-Premise
of I-Premise
obstructive I-Premise
symptoms I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low O
- O
grade O
, O
non O
- O
Hodgkin O
' O
s O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

The B-Premise
survival I-Premise
benefit I-Premise
, I-Premise
adjusted I-Premise
for I-Premise
prognostic I-Premise
factors I-Premise
in I-Premise
a I-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
remained I-Premise
significant I-Premise
( I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise

Ongoing O
studies O
are O
exploring O
alternate O
schedules O
to O
maximize O
synergy O
between O
these O
agents O
. O

Incidence B-Premise
of I-Premise
adverse I-Premise
events I-Premise
was I-Premise
consistent I-Premise
with I-Premise
previously I-Premise
reported I-Premise
rates I-Premise
. I-Premise

Clinical B-Premise
benefits I-Premise
, I-Premise
including I-Premise
an I-Premise
overall I-Premise
survival I-Premise
advantage I-Premise
, I-Premise
were I-Premise
also I-Premise
seen I-Premise
in I-Premise
women I-Premise
who I-Premise
crossed I-Premise
over I-Premise
from I-Premise
placebo I-Premise
to I-Premise
letrozole I-Premise
after I-Premise
unblinding I-Premise
, I-Premise
indicating I-Premise
that I-Premise
tumors I-Premise
remain I-Premise
sensitive I-Premise
to I-Premise
hormone I-Premise
therapy I-Premise
despite I-Premise
a I-Premise
prolonged I-Premise
period I-Premise
since I-Premise
discontinuation I-Premise
of I-Premise
tamoxifen I-Premise
. I-Premise

The B-Premise
linear I-Premise
analogue I-Premise
self I-Premise
- I-Premise
assessment I-Premise
scale I-Premise
was I-Premise
less I-Premise
but I-Premise
significantly I-Premise
efficient I-Premise
for I-Premise
detection I-Premise
of I-Premise
treatment I-Premise
effects I-Premise
, I-Premise
with I-Premise
relative I-Premise
efficiency I-Premise
estimates I-Premise
ranging I-Premise
from I-Premise
0 I-Premise
. I-Premise
16 I-Premise
to I-Premise
2 I-Premise
. I-Premise
45 I-Premise
and I-Premise
a I-Premise
median I-Premise
of I-Premise
0 I-Premise
. I-Premise
66 I-Premise
among I-Premise
the I-Premise
comparisons I-Premise
with I-Premise
relatively I-Premise
stable I-Premise
estimates I-Premise
( I-Premise
\/ I-Premise
t I-Premise
\/ I-Premise
> I-Premise
or I-Premise
= I-Premise
1 I-Premise
. I-Premise
0 I-Premise
) I-Premise
and I-Premise
more I-Premise
efficient I-Premise
for I-Premise
recurrence I-Premise
than I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2 I-Premise
- I-Premise
year I-Premise
DFS I-Premise
79 I-Premise
. I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76 I-Premise
. I-Premise
4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2 I-Premise
- I-Premise
year I-Premise
OS I-Premise
83 I-Premise
. I-Premise
1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84 I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
925 I-Premise
) I-Premise
. I-Premise

Group B-Premise
CBT I-Premise
significantly I-Premise
reduced I-Premise
HFNS I-Premise
problem I-Premise
rating I-Premise
at I-Premise
9 I-Premise
weeks I-Premise
after I-Premise
randomisation I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
· I-Premise
67 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
- I-Premise
2 I-Premise
· I-Premise
43 I-Premise
to I-Premise
- I-Premise
0 I-Premise
· I-Premise
91 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
and I-Premise
improvements I-Premise
were I-Premise
maintained I-Premise
at I-Premise
26 I-Premise
weeks I-Premise
( I-Premise
mean I-Premise
difference I-Premise
- I-Premise
1 I-Premise
· I-Premise
76 I-Premise
, I-Premise
- I-Premise
2 I-Premise
· I-Premise
54 I-Premise
to I-Premise
- I-Premise
0 I-Premise
· I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
12 I-Premise
. I-Premise
1 I-Premise
months I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0 I-Premise
. I-Premise
99 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0 I-Premise
. I-Premise
85 I-Premise
- I-Premise
1 I-Premise
. I-Premise
15 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
93 I-Premise
] I-Premise
. I-Premise

Recently B-Claim
, I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
by I-Claim
continuous I-Claim
infusion I-Claim
of I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
FU I-Claim
) I-Claim
with I-Claim
low I-Claim
- I-Claim
dose I-Claim
cisplatin I-Claim
( I-Claim
CDDP I-Claim
) I-Claim
has I-Claim
improved I-Claim
efficacy I-Claim
without I-Claim
severe I-Claim
toxicities I-Claim
. I-Claim

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

The B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
GE I-Premise
15 I-Premise
. I-Premise
5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27 I-Premise
. I-Premise
7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0 I-Premise
. I-Premise
20 I-Premise
) I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
for I-Premise
the I-Premise
gemcitabine I-Premise
- I-Premise
carboplatin I-Premise
group I-Premise
was I-Premise
47 I-Premise
. I-Premise
2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
39 I-Premise
. I-Premise
9 I-Premise
- I-Premise
54 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
and I-Premise
30 I-Premise
. I-Premise
9 I-Premise
% I-Premise
for I-Premise
carboplatin I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
24 I-Premise
. I-Premise
1 I-Premise
- I-Premise
37 I-Premise
. I-Premise
7 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
0016 I-Premise
) I-Premise
. I-Premise

The B-Claim
efficacy I-Claim
of I-Claim
5 I-Claim
- I-Claim
FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S I-Claim
- I-Claim
LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin I-Claim
- I-Claim
containing I-Claim
regimens I-Claim
. I-Claim

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

No B-Premise
changes I-Premise
were I-Premise
found I-Premise
in I-Premise
arm I-Premise
circumference I-Premise
or I-Premise
arm I-Premise
volume I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
exercise I-Premise
program I-Premise
. I-Premise

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
occurred I-Premise
and I-Premise
more I-Premise
reinterventions I-Premise
were I-Premise
performed I-Premise
( I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
01 I-Premise
) I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow I-Premise
- I-Premise
up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11 I-Premise
. I-Premise
1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10 I-Premise
. I-Premise
2 I-Premise
to I-Premise
15 I-Premise
. I-Premise
0 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
FU24h I-Premise
, I-Premise
13 I-Premise
. I-Premise
0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10 I-Premise
. I-Premise
4 I-Premise
to I-Premise
15 I-Premise
. I-Premise
4 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13 I-Premise
. I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12 I-Premise
. I-Premise
0 I-Premise
to I-Premise
16 I-Premise
. I-Premise
4 I-Premise
months I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
724 I-Premise
) I-Premise
. I-Premise

Lower B-Claim
dosages I-Claim
of I-Claim
HRT I-Claim
were I-Claim
as I-Claim
effective I-Claim
as I-Claim
higher I-Claim
doses I-Claim
in I-Claim
improving I-Claim
climacteric I-Claim
symptoms I-Claim
and I-Claim
HRQOL I-Claim
ratings I-Claim
and I-Claim
had I-Claim
fewer I-Claim
safety I-Claim
concerns I-Claim
. I-Claim

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
treatment I-Premise
- I-Premise
related I-Premise
AEs I-Premise
were I-Premise
asthenia I-Premise
\/ I-Premise
fatigue I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hypertension I-Premise
( I-Premise
11 I-Premise
% I-Premise
) I-Premise
, I-Premise
hand I-Premise
- I-Premise
foot I-Premise
syndrome I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
anorexia I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
lymphedema I-Premise
during I-Premise
the I-Premise
study I-Premise
was I-Premise
low I-Premise
for I-Premise
both I-Premise
groups I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
groups I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4 I-Premise
. I-Premise
3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4 I-Premise
. I-Premise
4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
81 I-Premise
) I-Premise
. I-Premise

The B-Premise
trial I-Premise
was I-Premise
stopped I-Premise
early I-Premise
because I-Premise
of I-Premise
poor I-Premise
accrual I-Premise
before I-Premise
the I-Premise
target I-Premise
of I-Premise
123 I-Premise
evaluable I-Premise
patients I-Premise
was I-Premise
met I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0 I-Premise
. I-Premise
05 I-Premise
and I-Premise
0 I-Premise
. I-Premise
01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Docetaxel B-Claim
- B-Claim
carboplatin B-Claim
appears I-Claim
to I-Claim
be I-Claim
similar I-Claim
to I-Claim
paclitaxel I-Claim
- I-Claim
carboplatin I-Claim
in I-Claim
terms I-Claim
of I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
and I-Claim
response I-Claim
, I-Claim
although B-Claim
longer I-Claim
follow I-Claim
- I-Claim
up I-Claim
is I-Claim
required I-Claim
for I-Claim
a I-Claim
definitive I-Claim
statement I-Claim
on I-Claim
survival I-Claim
. I-Claim

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

This B-Claim
study I-Claim
shows I-Claim
that I-Claim
the I-Claim
higher I-Claim
frequency I-Claim
of I-Claim
toxicity I-Claim
associated I-Claim
with I-Claim
MPT I-Claim
does I-Claim
not I-Claim
translate I-Claim
into I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQoL I-Claim
and I-Claim
that I-Claim
MPT I-Claim
holds I-Claim
a I-Claim
better I-Claim
patient I-Claim
perspective I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

However B-Claim
, I-Claim
HRQoL I-Claim
is I-Claim
not I-Claim
compromised I-Claim
in I-Claim
the I-Claim
long I-Claim
term I-Claim
, I-Claim
recovering I-Claim
by I-Claim
the I-Claim
end I-Claim
- I-Claim
of I-Claim
- I-Claim
treatment I-Claim
visit I-Claim
to I-Claim
be I-Claim
comparable I-Claim
vs I-Claim
. I-Claim
MP I-Claim
. I-Claim

"""" B-Claim
Laying I-Claim
on I-Claim
of I-Claim
hands I-Claim
"""" I-Claim
resulted I-Claim
in I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
cancer I-Claim
- I-Claim
or I-Claim
cancer I-Claim
- I-Claim
therapy I-Claim
- I-Claim
associated I-Claim
symptoms I-Claim
. I-Claim

DC B-Claim
\/ B-Claim
CIK B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
. I-Claim

Carboplatin B-Claim
\/ B-Claim
vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
- I-Claim
stage I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
postoperative I-Claim
clinical I-Claim
superiority I-Claim
of I-Claim
the I-Claim
interposition I-Claim
of I-Claim
jejunum I-Claim
reconstruction I-Claim
( I-Claim
INT I-Claim
) I-Claim
to I-Claim
Roux I-Claim
- I-Claim
en I-Claim
- I-Claim
Y I-Claim
reconstruction I-Claim
( I-Claim
RY I-Claim
) I-Claim
after I-Claim
total I-Claim
gastrectomy I-Claim
has I-Claim
not I-Claim
been I-Claim
clarified I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
this I-Claim
first I-Claim
randomized I-Claim
study I-Claim
did I-Claim
not I-Claim
demonstrate I-Claim
any I-Claim
significant I-Claim
improvement I-Claim
of I-Claim
using I-Claim
estramustine I-Claim
in I-Claim
addition I-Claim
to I-Claim
conventional I-Claim
radiotherapy I-Claim
, I-Claim
however B-Claim
, I-Claim
a I-Claim
trend I-Claim
for I-Claim
a I-Claim
positive I-Claim
response I-Claim
for I-Claim
the I-Claim
estramustine I-Claim
group I-Claim
was I-Claim
found I-Claim
in I-Claim
patients I-Claim
with I-Claim
grade I-Claim
III I-Claim
glioma I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse I-Claim
- I-Claim
led I-Claim
, I-Claim
palliative I-Claim
care I-Claim
- I-Claim
focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
ICU I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim

These B-Claim
data I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
4 I-Claim
. I-Claim
5 I-Claim
- I-Claim
month I-Claim
median I-Claim
OS I-Claim
advantage I-Claim
with I-Claim
the I-Claim
lapatinib I-Claim
and I-Claim
trastuzumab I-Claim
combination I-Claim
and I-Claim
support I-Claim
dual I-Claim
HER2 I-Claim
blockade I-Claim
in I-Claim
patients I-Claim
with I-Claim
heavily I-Claim
pretreated I-Claim
HER2 I-Claim
- I-Claim
positive I-Claim
MBC I-Claim
. I-Claim

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well I-Claim
- I-Claim
being I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow I-Claim
- I-Claim
up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse I-Claim
- I-Claim
led I-Claim
telephone I-Claim
follow I-Claim
- I-Claim
up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

All B-Claim
the I-Claim
three I-Claim
opioids I-Claim
used I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
were I-Claim
effective I-Claim
, I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
and I-Claim
required I-Claim
similar I-Claim
amounts I-Claim
of I-Claim
symptomatic I-Claim
drugs I-Claim
or I-Claim
co I-Claim
- I-Claim
analgesics I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
ARSR I-Claim
between I-Claim
patients I-Claim
randomised I-Claim
to I-Claim
Calendula I-Claim
or I-Claim
Essex I-Claim
cream I-Claim
was I-Claim
found I-Claim
. I-Claim

We B-Claim
found I-Claim
no I-Claim
evidence I-Claim
that I-Claim
the I-Claim
addition I-Claim
of I-Claim
TPZ I-Claim
to I-Claim
chemoradiotherapy I-Claim
, I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
not I-Claim
selected I-Claim
for I-Claim
the I-Claim
presence I-Claim
of I-Claim
hypoxia I-Claim
, I-Claim
improves I-Claim
OS I-Claim
. I-Claim

An B-Claim
unplanned I-Claim
safety I-Claim
analysis I-Claim
suggested I-Claim
decreased I-Claim
overall I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
treated I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

The B-Claim
LV5FU2 I-Claim
- I-Claim
oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first I-Claim
- I-Claim
line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
QoL I-Claim
. I-Claim

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non I-Claim
- I-Claim
stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

Docetaxel B-Claim
has I-Claim
shown I-Claim
activity I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Improvements B-Claim
in I-Claim
total I-Claim
quality I-Claim
- I-Claim
of I-Claim
- I-Claim
life I-Claim
change I-Claim
scores I-Claim
demonstrated I-Claim
that I-Claim
at I-Claim
6 I-Claim
months I-Claim
, I-Claim
improvements I-Claim
were I-Claim
more I-Claim
than I-Claim
twice I-Claim
as I-Claim
large I-Claim
and I-Claim
clinically I-Claim
significant I-Claim
in I-Claim
the I-Claim
intervention I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
. I-Claim

VC B-Claim
, I-Claim
GC I-Claim
, I-Claim
and I-Claim
TC I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
PC I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

It B-Claim
has I-Claim
been I-Claim
shown I-Claim
that I-Claim
nonpharmacologic I-Claim
interventions I-Claim
are I-Claim
effective I-Claim
management I-Claim
techniques I-Claim
for I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
( I-Claim
CRF I-Claim
) I-Claim
in I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

Intraperitoneal B-Claim
perfusion I-Claim
of I-Claim
verapamil I-Claim
enhances I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
chemotherapy I-Claim
drugs I-Claim
, I-Claim
prolongs I-Claim
survival I-Claim
, I-Claim
and I-Claim
improves I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

However B-Claim
, I-Claim
modifications I-Claim
are I-Claim
needed I-Claim
in I-Claim
future I-Claim
randomized I-Claim
trials I-Claim
to I-Claim
reduce I-Claim
the I-Claim
rate I-Claim
of I-Claim
premature I-Claim
termination I-Claim
and I-Claim
to I-Claim
improve I-Claim
long I-Claim
- I-Claim
term I-Claim
maintenance I-Claim
of I-Claim
gains I-Claim
. I-Claim

